Industry: Healthcare
Published Date: April-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 134
Report ID: PMRREP33045
1. Executive Summary
1.1. U.S. Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Application Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology
4.2. Key Promotional Strategies
4.3. Key Regulations
4.4. Value Chain Analysis
4.5. Pipeline Analysis
4.6. Recommendations for RSV
4.7. PESTLE Analysis
4.8. PORTER Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. U.S. GDP Growth Outlook
5.1.2. U.S. Healthcare Expenditure Outlook
5.1.3. Research & Development Funding
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Life Science research and development activities
5.2.2. Disease Epidemiology
5.2.3. Treatment Adoption Analysis
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. U.S. Respiratory Syncytial Virus Vaccines Market Demand Value (US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032
6.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
6.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. U.S. Respiratory Syncytial Virus Vaccines Market Analysis 2019-2023 and Forecast 2024-2032, By Drug Type
7.1. Introduction / Key Findings
7.2. Historical Market Value (US$ Mn) By Drug Type , 2019-2023
7.3. Current and Future Market Value (US$ Mn) Analysis and Forecast By Drug Type , 2024-2032
7.3.1. Palivizumab
7.3.2. RSVpreF PF06928316
7.3.3. RSVPreF3 OA (GSK3844766A)
7.3.4. mRNA-1345
7.3.5. mRNA-1345
7.3.6. Janssen RSV Vaccine
7.3.7. ResVax
7.3.8. Nirsevimab (MEDI8897)
7.3.9. MVA-BN RSV
8. U.S. Respiratory Syncytial Virus Vaccines Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel
8.1. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
8.2. Current and Future Market Material (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2032
8.2.1. Institutional Sales
8.2.1.1. Hospitals
8.2.1.2. Specialty Clinics
8.2.1.3. Academic and Research Institutes
8.2.2. Retail Sales
8.2.2.1. Retail Pharmacy
8.2.2.2. Drug Stores
8.2.3. Online Sales
9. Competition Analysis
9.1. Competition Dashboard
9.2. Competition Deep Dive
9.2.1. Pfizer Inc.
9.2.1.1. Overview
9.2.1.2. Service Portfolio
9.2.1.3. Key Financials
9.2.1.4. Strategy Overview
9.2.2. Sanofi
9.2.2.1. Overview
9.2.2.2. Service Portfolio
9.2.2.3. Key Financials
9.2.2.4. Strategy Overview
9.2.3. Merck Sharp & Dohme
9.2.3.1. Overview
9.2.3.2. Service Portfolio
9.2.3.3. Key Financials
9.2.3.4. Strategy Overview
9.2.4. GlaxoSmithKline
9.2.4.1. Overview
9.2.4.2. Service Portfolio
9.2.4.3. Key Financials
9.2.4.4. Strategy Overview
9.2.5. SOBI
9.2.5.1. Overview
9.2.5.2. Service Portfolio
9.2.5.3. Key Financials
9.2.5.4. Strategy Overview
9.2.6. Johnson & Johnson
9.2.6.1. Overview
9.2.6.2. Service Portfolio
9.2.6.3. Key Financials
9.2.6.4. Strategy Overview
9.2.7. Bavarian Nordic
9.2.7.1. Overview
9.2.7.2. Service Portfolio
9.2.7.3. Key Financials
9.2.7.4. Strategy Overview
9.2.8. Novavax
9.2.8.1. Overview
9.2.8.2. Service Portfolio
9.2.8.3. Key Financials
9.2.8.4. Strategy Overview
9.2.9. AstraZeneca
9.2.9.1. Overview
9.2.9.2. Service Portfolio
9.2.9.3. Key Financials
9.2.9.4. Strategy Overview
9.2.10. Moderna, Inc.
9.2.10.1. Overview
9.2.10.2. Service Portfolio
9.2.10.3. Key Financials
9.2.10.4. Strategy Overview
9.2.11. Codagenix Inc.
9.2.11.1. Overview
9.2.11.2. Service Portfolio
9.2.11.3. Key Financials
9.2.11.4. Strategy Overview
9.2.12. Intravacc BV.
9.2.12.1. Overview
9.2.12.2. Service Portfolio
9.2.12.3. Key Financials
9.2.12.4. Strategy Overview
9.2.13. Alphavax, Inc.
9.2.13.1. Overview
9.2.13.2. Service Portfolio
9.2.13.3. Key Financials
9.2.13.4. Strategy Overview
10. Assumptions and Acronyms Used
11. Research Methodology
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Table 01: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032, By Drug Type
Table 02: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Figure 01: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market size (US$ Mn) 2022E & 2032F
Figure 02: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market Size (US$ Mn) Analysis, 2017-2021
Figure 03: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), Analysis, 2022-2032
Figure 04: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market Absolute $ Opportunity Analysis, 2022-2032
